## **EXHIBIT A**

Approved for use through 04/30/2003, 0MB 0551-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

U.S. Platent and Trademark Office, U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless to ordain a valid OMB control number
Complete if Known

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)
of 6

Sheet 1

Complete if Known					
Application Number	10/621,027				
Filing Date	July 16, 2003				
First Named Inventor	CHEUNG, Nai-Kong V.				
Art Unit	1623				
Examiner Name	Eric Olson				
Attorney Docket Number	639-B-PCT-US				

Examiner Initials*	Cite No.	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant
1140003	Number-Kind Code <sup>2 (Finness)</sup>	Applicant of Cited Document	Figures Appear		
	1	US- 7,070,778	07-04-2006	YVIN et al.	
	2	US- 7,030,101	04-18-2006	PAVLIAK et al.	
	3	US- 5,130,127	07-14-1992	HERLYN, Dorothee	
		US-			
		US-			
		US-	"   " " " " " " " " " " " " " " " " " "		
		US-			
		US-			
	l	US-			
		US-			
***************************************		US-	<del>- </del>	-	
	$\vdash$	US-			· · · · · · · · · · · · · · · · · · ·
		US-			
		US-			-
		U\$-			
		US-			
		US-		***************************************	
	_	US-			
	_	US-	+	-	

	FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	П	
нинав	140.	Country Code <sup>3</sup> "Number <sup>4</sup> "Kind Code <sup>6</sup> (if known)	MM-DD-YYYY	Applicant of Cited Document	Or Relevant Figures Appear	T°	
	16	WO 2007084661	07-26-2007	Sloan-Ketlering Institute for Concer Research			
	17	WO 2006085895	08-172006	Biopolymer Engineering Inc et al.			
	18	WO 2005049044	06-02-2005	Laboratoires Goemar SA			
	19	WO 2004030613	04-15-2004	University of Loursellin Rescorch Foundation, Inc.			
	20	WO 02058711	08-01-2002	Sican-Kettering Institute for Cancer Research			
	21	WO 2006119395	11-09-2006	Biopolymer Engineering			

١	Examiner Signature	Date Conside	red

"EXAMINER: Initial if reference considered, whether or not cliation is in conformance with MPEP 859. Draw line through classon if not in conformance and not considered, whether or not cliation is in conformance with MPEP 859. Draw line through classon if not in conformance and not considered, whether the property of the form of the conformance and not considered, but for the conformance and not considered and the conformance and not considered only of MPEP 950 to the first instead the document, by the two-lefter code (WIPD States) of States of States and States of State

The orderion of information is required by 37 CFR 197 and 1.98. The information is required to obtain or relatin a benefit by the public which is to fig fand by the USFTO to processing an application. Confidentially is provemed by 35 U.S.C. 12 and 37 CFR 1.14. This collection is estimated to late 2 houses to complete, including gathering, preparing, and submitting the completed application form to the USFTO. Time will vary depending upon the individual case. Any common the amount of time you require to complete this form ander suppositions for relating this buttent, should be sent to the Other Information Officer, U.S. Petant and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO. Commissionor for Patants, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTC/SB/06A (04-03)
Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Substitute for form 1449/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 2

Col	mplete if Known	
Application Number	10/621,027	
Filing Date	July 16, 2003	
First Named Inventor	CHEUNG, Nai-Kong V.	
Art Unit	1623	
Examiner Name	Eric Olson	
Attorney Docket Number	639-B-PCT-US	

			U. S. PATENT D	OCUMENTS	
Examiner nitials*	Cite No.1	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevan Figures Appear
		Number-Kind Code <sup>2 (f known)</sup>			Figures Appear
		US-			
		US-			-
		US-			
		US-			-
		US-			
		US-			
	-	US-			
		US-	<del>                                     </del>	***	
		US-			
		US-			
	_	US-	<del> </del>		
	$\vdash$	US-	_		
		US-	<del> </del>		

		FORE	GN PATENT DOCU	MENTS			
Examiner Initials*	Cite No.1		Foreign Patent Document	Publication Date	Name of Patentse or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	
	L	Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)	MM-DD-YYYY	T P P S S S S S S S S S S S S S S S S S	Or Relevant Figures Appear	T°	
	22	WO 0180807	11-01-2001	Goemar Lab SA			
	23	WO 2005027938	03-31-2005	Goemar Lab SA			
	24	WO 03004507	01-16-2003	Resurrich Centar for Eco-Environmental Sciences			
	25	WO 0168105	09-20-2001	Secietal Cooperative Contro Plantins Polytech & Res	presentation Control		
	26	WO 2005027936	03-31-2005	Laboratoires Goemar SA			
	27	EP0194851	09-17-1986	The Wistar Institute			

Signature	Conside	500
*EXAMINER: Initial if reference considered, whether or not citation is in	conformance with MPEP 609, Draw line thro	ough citation if not in conformance and n
considered. Include copy of this form with next communication to appli	cant. ' Applicant's unique citation designation	n number (optional). * See Kinds Codes

not e of USPTO Petient Documents at www.usplo.go or MPEP 901.0.4. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> Env Jupanese patent document, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indication on the document under WIPO Standard ST. 16 if possible. <sup>8</sup> Applicant is to place a check mark here if English language For Translation is attached.

Institution is situated.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USF10 be process) an application. Confidentially is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complicate including gathering typespream, and submitting the completed application from the USFTO. The will wave depending on the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Critica, U.S. Peter and Trademark Office, U.S. Peter and Trademark Office, U.S. Department of Commerce, Washington, CO 2023. DO NOT SEND FEES OR COMPLETED FORMS TO THAK ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

Substitute for form 1449/PTO INFORMATION DISCLOSURE Filing Date July 16, 2003 STATEMENT BY APPLICANT First Named Inventor CHEUNG, Nai-Kong V. Art Unit 1623 (Use as many sheets as necessary) Examiner Name Eric Olson Attorney Docket Number Sheet 3 of 6 639-B-PCT-US

		OTHER PRIOR ART-NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	4	U.S. Publication No. US-2006-0020128, January 26, 2006, Nai-Kong CHEUNG, "Therapy-Enhancing Glucan."	
	5	U.S. Publication No. US-2008-0188506, August 24, 2006, Nai-Kong CHEUNG, "Therapy-Enhancing Glucan."	
	6	U.S. Publication No. US-2007-0059310, March 15, 2007, Steven KAREL, "Therapeutic combination compositions and methods of using same."	
	7	U.S. Publication No. US-2006-0185700, July 27, 2006, OSTROFF et al., "Cancer therapy using whole glucan particles and antibodies."	
	8	U.S. Publication No. US-2005-0118187, June 2, 2005, Baofa YU, "Combinations and methods for treating neoplasms."	
	9	U.S. Publication No. US-2007-0134259, June 14, 2007, BUNDLE et al., "Methods and compositions for pharmacologically controlled targeted immunotherapy."	
*	10	U.S. Publication No. US-2007-0020232, January 25, 2007, ROSSIGNOL et al., "Compositions and methods for cancer immunotherapy."	
	11	U.S. Publication No. US-2006-0009419, January 12, 2006, Gordon D. ROSS, "Cancer Therapy using beta glucan and antibodies."	
	12	U.S. Publication No. US-2006-0208079, September 22, 2005, CASSONE et al., "Glucan-based vaccines."	
	13	U.S. Publication No. US-2002-0044919, April 18, 2002, Baofa YU, "Combinations and methods for treating neoplesms."	

Examiner	Date	
Signature	Considered	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Consideration (Intelligence of the English Intelligence of the English Integration (Intelligence of the English Intelligence of the English Intell amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

639-B-PCT-US

PTO/SB/088 (02-03)

U.S. Patent and Trademark Office, U.S. DEPARTMENT of COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information which it certains a saled ONS centrel number.

Complete If Known

Application 4 formation which it certains a saled ONS centrel number.

Complete If Known Substitute for form 1449/PTO INFORMATION DISCLOSURE Filing Date July 16, 2003 STATEMENT BY APPLICANT First Named Inventor CHEUNG, Nai-Kong V. Art Unit 1623 (Use as many sheets as necessary) Examiner Name Eric Olson

Attorney Docket Number

Sheet

af 6

		OTHER PRIOR ART-NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	14	U.S. Publication No, US-2006-0263355, November 23, 2006, QUAN et al., "Treatment of bone disorders."	
	15	U.S. Publication No. US-2002-0119928, August 29, 2002, MCANALLEY et al., 'Dietery supplement compositions.'	
	28	ADACHI et al., 1990, "Macrophage Activation in Vitro by Chemically Cross-Linked (1-3)-β-D-Glucans", Chem. Pharm. Bull., 38(4):988-992.	
	29	AZUMA, Ichiro, "Development of Immunostimulants in Japan", Immunostimulants: Now and Tomorrow, 41-56.	
	30	BLUHM et al., 1977, "The triple helical structure of lentinan, a linear β-(1→3)-D-glucan", Can J Chem, 55:293-299.	
	31	BOGWALD et al., 1982, "The Cytoxic Effect of Mouse Macrophages Stimulated in Vitro by a β-1,3-D-Glucan from Yeast Cell Walls", Scandinavian Journal of Immunology, 15:297-304.	
	32	CHIHARA et at., 1982, "Current Status and Perspectives of Immunomodulators of Microbial Origin", International Journal of Tissue Reactions, 4:207-225.	
	33	MAEDA et al., 1971, "Lentinan, a new immune-accelerator of cell-mediated responses", Nature, 229:634.	
	34	CHIHARA et al., 1970, "Fractionation and purification of the polysaccharides with Marked Antitumor Activity, Especially Lentinan, from Lentinus edodes (Berk.) Sing. (an Edible Mushroom)", Cancer Res, 30:2776-2781.	
	35	CHIHARA et al., 1981, "The antitumor polysaccharide Lentinan: an overview", Manipulation of Host Defence Mechanisms, 1-16.	
	1		

Examiner	Date	
Signature	Considered	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered. Include copy of the form with next communications to appreciant sizes a check, may here if English language Tentiation is a statistical.

1 Applicant's study calculation designation number (optionally Applicant is to be a check, may here if English language Tentiation is a statistical.

1 Applicant's study calculation designation number (optionally Applicant) is considered to the statistical statistical statistical statistical statistical benefit by the problem which is to file (and by the USFTO to process) an application. Confidentially is provinced by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minus the compreted application from the full statistical form the full statistical statis statistical statistical statistical statistical statistical sta amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

Approved for use through 04/30/2003, OMB 0651-0031

639-B-PCT-US

Approved for use structing and success. Only bost relative to the structure of the structur Complete If Known Substitute for form 1449/PTO Application Number 10/621,027 INFORMATION DISCLOSURE Filing Date July 16, 2003 STATEMENT BY APPLICANT First Named Inventor CHEUNG, Nai-Kong V. Art Unit 1623 (Use as many sheets as necessary) Examiner Name Eric Olson

Attorney Docket Number

Sheet 5

of 6

		OTHER PRIOR ART-NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1		
	36	CHIHARA et al., 1987 "Antitumor and Metastasis-Inhibitory Activities of Lentinan as an Immunomodulator: An Overview", Cancer Detect. Prev. Suppl, 1:423-443.{	
	37	DI LUZIO et al., 1985, "Glucans as Immunomodulators", Advances in Immunopharmacology, Permagon Press, NY, 369-375	
	38	DI LUZIO et al., 1980, "Comparative Evaluation of the Turnor Inhibitory and Antibacterial Activity of Solubilized and Particulate Glucan", Recent Results in Cancer Research, 75:165-172.	
	39	DI LUZIO, Nicholas R., 1985, "Update on the Immunomodulating Activities of Glucans", Springer Seminars in Immunopathology, 8:387-400.	
	40	HAMURO et al., 1971, "The significance of the higher structure of the polysaccharides lentinan and pachymaran with regard to their antitumour activity", Chem. Biol. Interactions, 3:69-71.	
	41	HAMURO et al., 1978, "Solid phase activation of alternative pathway of complement by β-1,3-glucans and its possible role for tumour regressing activity", Immunology, 34:695-705.	
	42	JAMAS et al., 1990, "Spectral Analysis of Glucan Produced by Wild-Type and Mutant Seccharomyces cerevisiae", Carbohydrate Polymers, 13:207-219.	
	43	PATCHEN et al., 1984, "Soluble Polyglycans Enhance Recovery from Cobalt-60-Induced Hemopoietic Injury", Journal of Biological Response Modifiers, 3:627-633.	
	44	SAITO et al., 1977, "A C-N.M.Rspectral study of a gel forming, branched (1—3)-β-D-Glucan, (Lenfinan) from Lenfinus edodes, and its acid-degraded fractions. Structure, and Dependence of Confirmation on the Molecular Weight", Carboyrdera Research, 58:293-305.	
	45	SASAKI et al., 1976, "Antitumor Activity of Degraded Products of Lentinan: it's Correlation with Molecular Weight", Gann, 67:191-195.	

Examiner	Date
Signature	Considered

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant,

Applicant's unique distaint designation number (policans). Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1,98. The information is required to obtain or retain a benefit by the public which is to fill (and by the USPTO). to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case, recommendation of time to unrequire to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, USP pleafed and Tradomant Officer, USP Department of Commerce, Westington, DC 20231. DO NOT SEND TEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO. Commissioner for Patents, Washington, DC 20231.

PTC/SB/08B (02-03)
Approved for use through 04/30/2003, OMB 0551-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449/PTO				re required to respond to a collection of information unless it contains a valid OMB control number.  Complete If Known		
				Application Number	10/621,027	
INFO	ORMATION	DIS	CLOSURE	Filing Date	July 16, 2003	
STATEMENT BY APPLICANT (Use as many sheets as necessary)				First Named Inventor	CHEUNG, Nai-Kong V.	
				Art Unit	1623	
				Examiner Name	Eric Olson	
Sheet	6	of	6	Attorney Docket Number	639-B-PCT-US	

Examiner	Cite	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of	
initials*	No.1	the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	46	SELJELID et al., 1977, "Glycan Stimulation of Macrophages in Vitro", Experimental Cell Research, 131:121-129.	
	47	SINGH et al., 1974, "Scleroglucan, an antitumor polysaccharide from Sclerofium glucanicum", Carbohydrate Research, 37:245-247.	
	48	SUZUKI et al., 1989, "Immunomodulation by Orally Administered β-Glucan in Mice", International Journal of Immunopharmacology, 11:761-769.	
	49	KIRBY et al., 1981, "Ost-bran intake selectively lowers serum low-density lipoprotein cholesterol concentrations of hypercholesterolemic men", American Journal of Clinical Nutrition, 34:824-829.	
	50	PEAT et al., 1958, "Polysaccharides of Baker's Yeast. Part II. Yeast Glucan", Journal Chem. Soc. Part 1, 3862-3968.	
			$\vdash$

Examiner	*	Date	*
Signature		Considered	1

EXAMINER: Initial if reference considered, whether or not dilation is in conformance with MPEP 609. Draw tine through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered. Include copy of the form with next communication to applicant.

If Applicant's useful custom designation customer's optional, 2-Applicant is to puise a cheek mark near it it is regular impaired in the property of the property Commissioner for Patents, Washington, DC 20231.